New York-based gene therapy company MeiraGTx has raised USD 50 million in an underwritten offering of 12.5 million ordinary shares at USD 4 per share. The financing was led by Sanofi with a USD 30 million investment and included participation from Perceptive Advisors and other institutional healthcare funds.
The company intends to use the proceeds from the offering, although specific details on the use of funds were not provided. The offering is expected to close on or about August 13, 2024, subject to customary closing conditions.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.